1. Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009; 74: 1405-1418.
2.
Al-Mamgani A, van Putten WLJ, Heemsbergen WD et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72: 980-988.
3.
Michalski JM, Moughan J, Purdy J et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol 2018; 4: e180039.
4.
Morton G, Loblaw A, Cheung P et al. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer? Radiother Oncol 2011; 100: 463-467.
5.
Pellizzon ACA. Radiation treatment of prostate cancers – the contemporary role of modern brachytherapy techniques. J Contemp Brachytherapy 2017; 9: 391-392.
6.
Kishan AU, Cook RR, Ciezki JP et al. Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with gleason score 9-10 prostate cancer. JAMA 2018; 319: 896-905.
7.
Morris WJ, Tyldesley S, Rodda S et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017; 98: 275-285.
8.
Sathya JR, Davis IR, Julian JA et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005; 23: 1192-1199.
9.
Xiang M, Nguyen PL. Significant association of brachytherapy boost with reduced prostate cancer-specific mortality in contemporary patients with localized, unfavorable-risk prostate cancer. Brachytherapy 2015; 14: 773-780.
10.
Wedde TB, Småstuen MC, Brabrand S et al. Ten-year survival after high-dose-rate brachytherapy combined with external beam radiation therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort. Radiother Oncol 2019; 132: 211-217.
11.
Hoskin PJ, Rojas AM, Bownes PJ et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012; 103: 217-222.
12.
Martell K, Kollmeier MA. Complications and side effects of high-dose-rate prostate brachytherapy. Brachytherapy 2021; 20: 966-975.
13.
Tamihardja J, Lawrenz I, Lutyj P et al. Propensity score-matched analysis comparing dose-escalated intensity-modulated radiation therapy versus external beam radiation therapy plus high-dose-rate brachytherapy for localized prostate cancer. Strahlenther Onkol 2022; 198: 735-743.
14.
Rodda S, Tyldesley S, Morris WJ et al. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017; 98: 286-295.
15.
Oh J, Tyldesley S, Pai H et al. An updated analysis of survival endpoints for ASCENDE-RT, a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2020; 108: S62.
16.
Parry MG, Nossiter J, Sujenthiran A et al. Impact of high-dose-rate and low-dose-rate brachytherapy boost on toxicity, functional and cancer outcomes in patients receiving external beam radiation therapy for prostate cancer: A national population-based study. Int J Radiat Oncol Biol Phys 2021; 109: 1219-1229.
17.
D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974.
18.
Yu JB, Makarov DV, Gross C. A new formula for prostate cancer lymph node risk. Int J Radiat Oncol Biol Phys 2011; 80: 69-75.
19.
Stromberg JS, Martinez AA, Horwitz EM et al. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment. Cancer J Sci Am 1997; 3: 346-352.
20.
Lettmaier S, Lotter M, Kreppner S et al. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer. Radiother Oncol 2012; 104: 181-186.
21.
Roach M, 3rd, Hanks G, Thames Jr H et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-974.
22.
Joseph D, Denham JW, Steigler A et al. Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-year data from the TROG 03.04 RADAR trial. Int J Radiat Oncol Biol Phys 2020; 106: 693-702.
23.
Denham JW, Joseph D, Lamb DS et al. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. Lancet Oncol 2019; 20: 267-281.
24.
Denham JW, Wilcox C, Lamb DS et al. Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer. Radiother Oncol 2012; 105: 184-192.
25.
Hoskin PJ, Rojas AM, Ostler PJ et al. Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results. Radiother Oncol 2021; 154: 214-219.
26.
Martell K, Mendez LC, Chung HT et al. Results of 15 Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: Analysis of over 500 patients. Radiother Oncol 2019; 141: 149-155.
27.
Henry A, Pieters BR, Siebert FA et al. GEC-ESTRO ACROP prostate brachytherapy guidelines. Radiother Oncol 2022; 167: 244-251.
28.
Neal DE, Metcalfe C, Donovan JL et al. Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protecT randomised controlled trial according to treatment received. Eur Urol 2020; 77: 320-330.
29.
Wilt TJ, Brawer MK, Jones KM et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203-213.
30.
Dhere VR, Fischer-Valuck BW, Goyal S et al. Patient-reported outcomes after low-dose-rate versus high-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer. Brachytherapy 2021; 20: 1130-1138.
31.
Knoth J, Konrad S, Lössl K et al. Survey on brachytherapy training among radiation oncology residents in the German-speaking regions of Europe. Strahlenther Onkol 2023; 199: 798-805.
32.
Banerjee S, Sarkar S, Mahantshetty U et al. Current status and future readiness of Indian radiation oncologists to embrace prostate high-dose-rate brachytherapy: An Indian Brachytherapy Society survey. J Contemp Brachytherapy 2023; 15: 391-398.
33.
Fowler JF, Van Limbergen EF. Biological effect of pulsed dose rate brachytherapy with stepping sources if short half-times of repair are present in tissues. Int J Radiat Oncol Biol Phys 1997; 37: 877-883.
34.
Rogers CL, Freel JH, Speiser BL. Pulsed low dose rate brachytherapy for uterine cervix carcinoma. Int J Radiat Oncol Biol Phys 1999; 43: 95-100.
35.
Sonnhoff M, Graff M, Paal K et al. Influence of demographic change on the demand for radiotherapy using forecasted predictions for prostate cancer in Germany. Strahlenther Onkol 2024; 200: 671-675.
36.
Paal K, Stranz B, Thurner EM et al. Comprehensive geriatric assessment predicts radiation-induced acute toxicity in prostate cancer patients. Strahlenther Onkol 2024; 200: 208-218.
37.
Chin J, Rumble RB, Kollmeier M et al. Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update. J Clin Oncol 2017; 35: 1737-1743.
38.
Sanmamed N, Lee J, Berlin A et al. Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life. Radiother Oncol 2020; 149: 240-245.
39.
Strnad V, Lotter M, Kreppner S et al. Brachytherapy focal dose escalation using ultrasound based tissue characterization by patients with non-metastatic prostate cancer: Five-year results from single-center phase 2 trial. Brachytherapy 2022; 21: 415-423.
40.
Kerkmeijer LGW, Groen VH, Pos FJ et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: Results from the FLAME randomized phase III trial. J Clin Oncol 2021; 39: 787-796.
41.
Zamboglou C, Spohn SKB, Ruf J et al. PSMA-PET- and MRI-based focal dose escalated radiation therapy of primary prostate cancer: Planned safety analysis of a nonrandomized 2-Armed Phase 2 Trial (ARO2020-01). Int J Radiat Oncol Biol Phys 2022; 113: 1025-1035.
42.
Monninkhof EM, van Loon JWL, van Vulpen M et al. Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial. Radiother Oncol 2018; 127: 74-80.
